Business Context and Reporting Period
Company: Eli Lilly & Co.
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Quarter and six months ended June 30, 2000.
Business Overview: The company operates primarily in pharmaceutical products, with a non-material animal health segment. Performance is evaluated based on profit or loss from operations before income taxes.
Key Financial Metrics
| Metric (in millions) | Q2 2000 | Q2 1999 | 6M 2000 | 6M 1999 |
|---|---|---|---|---|
| Net Sales | $2,621.5 | $2,341.6 | $5,072.6 | $4,597.2 |
| Cost of Sales | $491.7 | $491.1 | $1,000.4 | $984.6 |
| Gross Margin % | 81.2% | 79.0% | 80.3% | 78.6% |
| Income from Continuing Ops | $666.2 | $576.4 | $1,511.7 | $1,027.8 |
| Net Income | $666.2 | $576.4 | $1,511.7 | $1,202.1 |
| Diluted EPS (Continuing Ops) | $0.61 | $0.52 | $1.38 | $0.92 |
| Operating Cash Flow (6M) | $1,411.3 (2000) vs $607.1 (1999) | |||
| Cash & Equivalents (End Period) | $3,370.5 | |||
| Total Debt | $2,847.5 (Short-term: $50.1 + Long-term: $2,797.4) |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 12% in Q2 2000 and 10% for the six-month period compared to 1999. Growth was driven by Zyprexa, diabetes care products (Humalog, Actos), Evista, and Gemzar.
- Product Performance:
- Zyprexa: Sales up 40% (Q2) and 27% (6M).
- Diabetes Care: Revenues up 24% (Q2) and 35% (6M).
- Prozac: Sales declined 9% (Q2) and 4% (6M) due to generic competition, particularly outside the U.S.
- Anti-infectives: Sales declined 2% (Q2) and 9% (6M) due to competitive pressures.
- Profitability: Income from continuing operations rose 16% in Q2 and 47% for the six-month period. Gross margins improved due to favorable product mix.
- Unusual Items Impact:
- 2000: A $214.4 million gain from the sale of Kinetra LLC interest boosted Q1 2000 earnings.
- 1999: A $174.3 million gain from the sale of PCS (discontinued operations) and a $150.0 million charitable contribution charge affected prior year comparability.
- Expenses: Operating expenses increased 17% (Q2) and 16% (6M) due to sales force expansion and marketing efforts. R&D expenses rose 10% (Q2) and 11% (6M).
Guidance, Outlook, and Risks
Management Commentary & Outlook
- Prozac Patent Litigation: On August 9, 2000, the U.S. Court of Appeals upheld the 2001 compound patent but invalidated the 2003 method-of-use patent. The company plans to appeal. If unsuccessful, U.S. patent protection ends February 2, 2001, potentially extended to August 1, 2001, via FDA exclusivity.
- Financial Impact of Prozac: Management expects a "very substantial decline" in U.S. Prozac sales upon generic entry. Prozac accounted for 21% of worldwide sales in the first six months of 2000.
- 2001-2002 Forecast: The company anticipates single-digit sales and earnings per share growth for calendar years 2001 and 2002, assuming generic entry in August 2001. Growth in other products is expected to offset Prozac declines in the first half of 2001 and second half of 2002.
- Liquidity: Cash generated from operations, combined with existing cash ($3.63 billion including short-term investments), is deemed sufficient to fund 2000 operating needs, debt service, capital expenditures, and a $3.0 billion share repurchase program announced in March 2000.
Risks and Contingencies
- Legal Proceedings: Ongoing litigation regarding Prozac patents with multiple generic manufacturers (Barr, Geneva, Teva, etc.). Product liability lawsuits involving DES and Prozac are accrued but covered largely by insurance.
- Environmental: Accrued liabilities for Superfund cleanup and remediation total approximately $157.2 million, with estimated insurance recoverables of $82.8 million.
- Accounting Changes: Adoption of SAB No. 101 (Revenue Recognition) and SFAS No. 133 (Derivatives) is expected to have no material effect on earnings, though foreign currency hedging impacts under SFAS 133 cannot yet be determined.
Investor Verification Checklist
- Prozac Patent Appeal Status: Verify the outcome of the appeal regarding the 2003 method-of-use patent and the likelihood of securing the 180-day FDA marketing exclusivity extension.
- Generic Competition Timeline: Monitor the entry dates and pricing strategies of generic fluoxetine manufacturers in the U.S. and international markets.
- Product Mix Sustainability: Assess the growth trajectory of Zyprexa, Evista, and diabetes products to ensure they can offset the projected decline in Prozac sales.
- Share Repurchase Execution: Track the progress of the $3.0 billion share repurchase program announced in March 2000.
- Legal Accruals: Review updates on product liability and environmental litigation accruals to ensure they remain adequate against potential judgments.